Nuclear energy is one of the least greenhouse gas (GHG) emitting energies in the world, with emissions comparable to wind power, 4 times lower than solar power and 40 times lower than gas. Its very small CO2 footprint makes it essential for the transition to low-carbon energy solutions.
*IPCC: Intergovernmental Panel on Climate Change
France has developed a complete national industrial sector that enables it to control the design and construction of its own facilities for electricity production, uranium enrichment, and fuel fabrication, not to mention recycling. With its technologies and industrial know-how, unlike any others in the world, Orano contributes to the excellence of the French nuclear sector.
With our 17 industrial locations in France, we represent dynamic job markets in several regions: Southern France, Normandy, Paris region, eastern France and central France. As key actors in the local economic fabric, our sites play a key role in regional structures by supporting jobs and training and by participating in the social economy of solidarity.
Processing and recycling used fuel makes it possible to recover the re-usable nuclear material to make new fuel (MOX) which will in turn generate electricity. By doing this, Orano participates in preserving natural resources.
Orano Med, the medical subsidiary of Orano, brings together biotechnologies and nuclear technologies to develop a new generation of therapies targeting cancer. It uses the unique properties of lead-212 (212Pb), a very rare radioactive isotope that comes from thorium. Orano’s expertise in cutting-edge nuclear technologies has made it possible to develop a unique process for extracting and purifying lead-212. This rare metal is the subject of a number of research projects and is used in several promising treatments targeting cancer, known as targeted alpha therapy.